Skip to main content
Top
Published in: Digestive Diseases and Sciences 3/2007

01-03-2007 | Original Paper

Clinical Evaluation of Lens Culinaris Agglutinin-Reactive α-Fetoprotein and Des-γ-Carboxy Prothrombin in Histologically Proven Hepatocellular Carcinoma in the United States

Authors: Brian I. Carr, Futoshi Kanke, Margaret Wise, Shinji Satomura

Published in: Digestive Diseases and Sciences | Issue 3/2007

Login to get access

Abstract

There is no established clinical role for the lens culinaris agglutinin-reactive fraction of α-fetoprotein (AFP-L3%) and des-γ-carboxy prothrombin (DCP) in the management of the U.S. hepatocellular carcinoma (HCC) patient population. In order to clarify the clinical usefulness and characteristics of AFP-L3% and DCP, a prospective study was performed on United States patients having histologically proven hepatocellular carcinoma. Ninety-nine histologically proven HCC patients, who were diagnosed with unresectable cancer between July 1999 and March 2001 at the Liver Cancer Center of the University of Pittsburgh Medical Center, were included for analysis. The sensitivity of AFP-L3%, DCP, and AFP was 61.6%, 72.7%, and 67.7%, respectively. The highest sensitivity, 85.9%, was obtained in the combination of three markers. Statistically significant differences were observed for portal vein invasion in AFP-L3% and AFP levels (P=0.0059 and P=0.0360, respectively). DCP was significantly associated with metastasis (P=0.0368). There were significant associations between AFP-L3% and AFP results and patient survival (P=0.0150 and P=0.0020, respectively). AFP-L3%, platelet count,and albumin showed a significant difference with respect to outcomes on Cox’s proportional hazard model (P=0.0059, P=0.0073, and P=0.0265, respectively). The combination of AFP-L3%, DCP, and AFP was determined to be superior for detection of HCC compared with each marker alone or to other combinations. AFP-L3% was significantly related to portal vein invasion and patient outcomes and appears to be a useful prognostic marker for HCC.
Literature
1.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden globocan 2000. Int J Cancer 94:153–156PubMedCrossRef Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden globocan 2000. Int J Cancer 94:153–156PubMedCrossRef
2.
go back to reference El-Serag HB (2004) Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127:S27–S34PubMedCrossRef El-Serag HB (2004) Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127:S27–S34PubMedCrossRef
3.
go back to reference Zaman SN, Melia WM, Johnson RD, Portmann BC, Johnson PJ, Williams R (1985) Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients. Lancet 1:1357–1360PubMedCrossRef Zaman SN, Melia WM, Johnson RD, Portmann BC, Johnson PJ, Williams R (1985) Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients. Lancet 1:1357–1360PubMedCrossRef
4.
go back to reference Poynard T, Aubert A, Lazizi Y, et al (1991) Independent risk factors for hepatocellular carcinoma in French drinkers. Hepatology 13:896–901PubMedCrossRef Poynard T, Aubert A, Lazizi Y, et al (1991) Independent risk factors for hepatocellular carcinoma in French drinkers. Hepatology 13:896–901PubMedCrossRef
5.
go back to reference Colombo M, Franchis Rd, Ninno ED, et al. (1991) Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 325:675–680PubMedCrossRef Colombo M, Franchis Rd, Ninno ED, et al. (1991) Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 325:675–680PubMedCrossRef
6.
go back to reference Tsukuma H, Hiyama T, Tanaka S, et al. (1993) The factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328:1797–1801PubMedCrossRef Tsukuma H, Hiyama T, Tanaka S, et al. (1993) The factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328:1797–1801PubMedCrossRef
7.
go back to reference Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C (1999) A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 31:133–141PubMedCrossRef Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C (1999) A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 31:133–141PubMedCrossRef
8.
go back to reference Bruix J SMPGC, American Association for the Study of Liver Diseases (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–1236CrossRef Bruix J SMPGC, American Association for the Study of Liver Diseases (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–1236CrossRef
9.
go back to reference Shinagawa T, Ohto M, Kimura K, et al. (1984) Diagnosis and clinical features of small hepatocellular carcinoma eith emphasis on the utility of real-time ultrasonography. Gastroenterology 86:495–502PubMed Shinagawa T, Ohto M, Kimura K, et al. (1984) Diagnosis and clinical features of small hepatocellular carcinoma eith emphasis on the utility of real-time ultrasonography. Gastroenterology 86:495–502PubMed
10.
go back to reference Ikeda K, Saitoh S, Koida I, et al. (1993) Diagnosis and follow-up of small hepatocellular carcinoma with selective intraarterial digital subtraction angiography. Hepatology 17:1003–1007PubMedCrossRef Ikeda K, Saitoh S, Koida I, et al. (1993) Diagnosis and follow-up of small hepatocellular carcinoma with selective intraarterial digital subtraction angiography. Hepatology 17:1003–1007PubMedCrossRef
11.
go back to reference Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S (1994) Prospective study of α-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 19:61–66PubMedCrossRef Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S (1994) Prospective study of α-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 19:61–66PubMedCrossRef
12.
go back to reference Takayasu K, Moriyama N, Muramatsu Y, et al. (1990) The diagnosis of small hepatocellular carcinoma: efficacy of various imaging procedures in 100 patients. AJR 155:49–54PubMed Takayasu K, Moriyama N, Muramatsu Y, et al. (1990) The diagnosis of small hepatocellular carcinoma: efficacy of various imaging procedures in 100 patients. AJR 155:49–54PubMed
13.
go back to reference Takayasu K, Furukawa H, Wakao F, et al. (1995) CT diagnosis of early hepatocellular carcinoma: sensitivity, findings, and CT-pathologic correlation. AJR 164:885–890PubMed Takayasu K, Furukawa H, Wakao F, et al. (1995) CT diagnosis of early hepatocellular carcinoma: sensitivity, findings, and CT-pathologic correlation. AJR 164:885–890PubMed
14.
go back to reference Ebara M, Ohto M, Watanabe Y, et al. (1986) Diagnosis of small hepatocellular carcinoma: Correlation of MR imaging and tumor histologic studies. Radiology 159:371–377PubMed Ebara M, Ohto M, Watanabe Y, et al. (1986) Diagnosis of small hepatocellular carcinoma: Correlation of MR imaging and tumor histologic studies. Radiology 159:371–377PubMed
15.
go back to reference Daniele B, Bencivenga A, Megna AS, Tinessa V (2004) α-Fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 127:S108–S12PubMedCrossRef Daniele B, Bencivenga A, Megna AS, Tinessa V (2004) α-Fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 127:S108–S12PubMedCrossRef
16.
go back to reference Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusion of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430PubMedCrossRef Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusion of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430PubMedCrossRef
17.
go back to reference Sheu JC, Sung JL, Chen DS, et al. (1985) Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study. Cancer 56:660–666PubMedCrossRef Sheu JC, Sung JL, Chen DS, et al. (1985) Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study. Cancer 56:660–666PubMedCrossRef
18.
go back to reference Taketa K, Sekiya C, Namiki M, et al. (1990) Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology 99:508–518PubMed Taketa K, Sekiya C, Namiki M, et al. (1990) Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology 99:508–518PubMed
19.
go back to reference Taketa K, Endo Y, Sekiya C, et al. (1993) A collaborative study for the evaluation of lectin-reactive a-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 53:19–23 Taketa K, Endo Y, Sekiya C, et al. (1993) A collaborative study for the evaluation of lectin-reactive a-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 53:19–23
20.
go back to reference Oka H, Saito A, Ito K, et al. (2001) Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of lens culinaris agglutinin-reactive a-fetoprotein. J Gastroenterol Hepatol 16:1378–1383PubMedCrossRef Oka H, Saito A, Ito K, et al. (2001) Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of lens culinaris agglutinin-reactive a-fetoprotein. J Gastroenterol Hepatol 16:1378–1383PubMedCrossRef
21.
go back to reference Sato Y, Nakata K, Kato Y, et al. (1993) Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 328:1802–1806PubMedCrossRef Sato Y, Nakata K, Kato Y, et al. (1993) Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 328:1802–1806PubMedCrossRef
22.
go back to reference Shiraki K, Takase K, Tameda Y, Hamada M, Kosaka Y, Nakano T (1995) A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology 22:802–807PubMedCrossRef Shiraki K, Takase K, Tameda Y, Hamada M, Kosaka Y, Nakano T (1995) A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology 22:802–807PubMedCrossRef
23.
go back to reference Yamashita F, Tanaka M, Satomura S, Tanikawa K (1995) Monitoring of lectin-reactive a-fetoprotein in patients with hepatocellular carcinoma treated using transcatheter arterial embolization. Eur J Gastroenterol Hepatol 7:627–633PubMed Yamashita F, Tanaka M, Satomura S, Tanikawa K (1995) Monitoring of lectin-reactive a-fetoprotein in patients with hepatocellular carcinoma treated using transcatheter arterial embolization. Eur J Gastroenterol Hepatol 7:627–633PubMed
24.
go back to reference Yamashita F, Tanaka M, Satomura S, Tanikawa K (1996) Prognostic significance of lens culinaris agglutinin A-reactive a-fetoprotein in small hepatocellular carcinomas. Gastroenterology 111:996–1001PubMedCrossRef Yamashita F, Tanaka M, Satomura S, Tanikawa K (1996) Prognostic significance of lens culinaris agglutinin A-reactive a-fetoprotein in small hepatocellular carcinomas. Gastroenterology 111:996–1001PubMedCrossRef
25.
go back to reference Hayashi K, Kumada T, Nakano S, et al. (1999) Usefulness of measurement of lens culinaris agglutinin-reactive fraction of α-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am J Gastroenterol 94:3028– 3033PubMed Hayashi K, Kumada T, Nakano S, et al. (1999) Usefulness of measurement of lens culinaris agglutinin-reactive fraction of α-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am J Gastroenterol 94:3028– 3033PubMed
26.
go back to reference Kumada T, Nakano S, Takeda I, et al. (1999) Clinical utility of lens culinaris aggulutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis. J Hepatol 30:125–130PubMedCrossRef Kumada T, Nakano S, Takeda I, et al. (1999) Clinical utility of lens culinaris aggulutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis. J Hepatol 30:125–130PubMedCrossRef
27.
go back to reference Tanaka M, Saito A, Ito K, et al. (2000) Lens culinaris agglutinin-reactive alpha-fetoprotein (AFP-L3) is the most significant prognostic factor for hepatocellular carcinoma after therapy. Hepatology 34:233A Tanaka M, Saito A, Ito K, et al. (2000) Lens culinaris agglutinin-reactive alpha-fetoprotein (AFP-L3) is the most significant prognostic factor for hepatocellular carcinoma after therapy. Hepatology 34:233A
28.
go back to reference Tada T, Kumada T, Toyoda H, et al. (2005) Relationship between lens culinaris agglutinin-reactive α-fetoprotein and pathologic features of hepatocellular carcinoma. Liver Int 25:1–6CrossRef Tada T, Kumada T, Toyoda H, et al. (2005) Relationship between lens culinaris agglutinin-reactive α-fetoprotein and pathologic features of hepatocellular carcinoma. Liver Int 25:1–6CrossRef
29.
go back to reference Ono M, Ohta H, Ohhira M, Sekiya C, Namiki M (1990) Measurement of immunoreactive prothrombin precursor and vitamin-K dependent gamma-carboxylation in human hepatocellular carcinoma tissues: decreased carboxylation of prothrombin precursor as a cause of des-gamma-carboxyprothrombin synthesis. Tumor Biol 11:319–326CrossRef Ono M, Ohta H, Ohhira M, Sekiya C, Namiki M (1990) Measurement of immunoreactive prothrombin precursor and vitamin-K dependent gamma-carboxylation in human hepatocellular carcinoma tissues: decreased carboxylation of prothrombin precursor as a cause of des-gamma-carboxyprothrombin synthesis. Tumor Biol 11:319–326CrossRef
30.
go back to reference Liebman HA (1989) Isolation and characterization of a hepatoma-associated abnormal (des-gamma carboxy) prothrombin. Cancer Res 49:6493–6497PubMed Liebman HA (1989) Isolation and characterization of a hepatoma-associated abnormal (des-gamma carboxy) prothrombin. Cancer Res 49:6493–6497PubMed
31.
go back to reference Aoyagi Y, Oguro M, Yanagi M, et al. (1996) Clinical significance of simultaneous determination of alpha-fetoprotein and des-gamma carboxyprothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer 77:1781–1786PubMedCrossRef Aoyagi Y, Oguro M, Yanagi M, et al. (1996) Clinical significance of simultaneous determination of alpha-fetoprotein and des-gamma carboxyprothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer 77:1781–1786PubMedCrossRef
32.
go back to reference Mita Y, Aoyagi Y, Yanagi M, Suda T, Suzuki Y, Asakura H (1998) The usefulness of determining des-gamma carboxyprothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 82:1643–1648PubMedCrossRef Mita Y, Aoyagi Y, Yanagi M, Suda T, Suzuki Y, Asakura H (1998) The usefulness of determining des-gamma carboxyprothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 82:1643–1648PubMedCrossRef
33.
go back to reference Nomura F, Ishijima M, Kuwa K, Tanaka N, Nakai T, Ohnishi K (1999) Serum des-gamma carboxyprothrombin levels determined by a new generation of sensitive immunoassay in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol 94:650–654PubMedCrossRef Nomura F, Ishijima M, Kuwa K, Tanaka N, Nakai T, Ohnishi K (1999) Serum des-gamma carboxyprothrombin levels determined by a new generation of sensitive immunoassay in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol 94:650–654PubMedCrossRef
34.
go back to reference Izuno K, Fujiyama S, Yamasaki K, Sato M, Sato T (1995) Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma carboxy prothrombin and alpha-fetoprotein: a prospective study. Hepatogastroenterology 42:387–393PubMed Izuno K, Fujiyama S, Yamasaki K, Sato M, Sato T (1995) Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma carboxy prothrombin and alpha-fetoprotein: a prospective study. Hepatogastroenterology 42:387–393PubMed
35.
go back to reference Ikoma J, Kaito M, Ishihara T, et al. (2002) Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma carboxy prothrombin: a prospective study. Hepatogastroenterology 49:235–238PubMed Ikoma J, Kaito M, Ishihara T, et al. (2002) Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma carboxy prothrombin: a prospective study. Hepatogastroenterology 49:235–238PubMed
36.
go back to reference Shimauchi Y, Tanaka M, Kuromatsu R, et al. (2000) A simultaneous monitoring of lens culinaris aggulutinin A-reactive alpha-fetoprotein and des-gamma carboxyprothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. Oncol Rep 7:249–256PubMed Shimauchi Y, Tanaka M, Kuromatsu R, et al. (2000) A simultaneous monitoring of lens culinaris aggulutinin A-reactive alpha-fetoprotein and des-gamma carboxyprothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. Oncol Rep 7:249–256PubMed
37.
go back to reference Ishii M, Gama H, Chida N, et al. (2000) Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. Am J Gastroenterol 95:1036–1040PubMed Ishii M, Gama H, Chida N, et al. (2000) Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. Am J Gastroenterol 95:1036–1040PubMed
38.
go back to reference Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K (2002) Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 62:57–63PubMedCrossRef Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K (2002) Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 62:57–63PubMedCrossRef
39.
go back to reference Okuda H, Nakanishi T, Takatsu K, et al. (2002) Clinicopathologic features of patients with hepatocellular carcinoma seropositive for a-fetoprotein-L3 and seronegative for des-g-carboxy prothrombin in comparison with those seropositive for des-g-carboxy prothrombin alone. J Gastroenterol Hepatol 17:772–778PubMedCrossRef Okuda H, Nakanishi T, Takatsu K, et al. (2002) Clinicopathologic features of patients with hepatocellular carcinoma seropositive for a-fetoprotein-L3 and seronegative for des-g-carboxy prothrombin in comparison with those seropositive for des-g-carboxy prothrombin alone. J Gastroenterol Hepatol 17:772–778PubMedCrossRef
40.
go back to reference Okuda H, Saito A, Haruyama K, et al. (2004) Unique clinicaopathological features of patients with primary malignant hepatic tumors who are seropositive for lectin-reactive α-fetoprotein alone: report of five cases. J Gastroenterol Hepatol 19:113–119PubMedCrossRef Okuda H, Saito A, Haruyama K, et al. (2004) Unique clinicaopathological features of patients with primary malignant hepatic tumors who are seropositive for lectin-reactive α-fetoprotein alone: report of five cases. J Gastroenterol Hepatol 19:113–119PubMedCrossRef
41.
go back to reference Okuda H, Saito A, Shiratori K, Yamamoto M, Takasaki K, Nakano M (2005) Clinicopathologic feature of patients with primary malignant hepatic tumors seropositive for a-fetoprotein-L3 alone in comparison with other patients seropositive for a-fetoprotein-L3. J Gastroenterol Hepatol 20:759–764PubMedCrossRef Okuda H, Saito A, Shiratori K, Yamamoto M, Takasaki K, Nakano M (2005) Clinicopathologic feature of patients with primary malignant hepatic tumors seropositive for a-fetoprotein-L3 alone in comparison with other patients seropositive for a-fetoprotein-L3. J Gastroenterol Hepatol 20:759–764PubMedCrossRef
42.
go back to reference Katoh H, Nakamura K, Tanaka T, Satomura S, Matsuura S (1998) Automatic and simultaneous analysis of Lens culinaris agglutinin-reactive alpha-fetoprotein ratio and total alpha-fetoprotein concentration. Anal Chem 70:2110–2114PubMedCrossRef Katoh H, Nakamura K, Tanaka T, Satomura S, Matsuura S (1998) Automatic and simultaneous analysis of Lens culinaris agglutinin-reactive alpha-fetoprotein ratio and total alpha-fetoprotein concentration. Anal Chem 70:2110–2114PubMedCrossRef
43.
go back to reference Yamagata Y, Katoh H, Nakamura K, Tanaka T, Satomura S, Matsuura S (1998) Determination of alpha-fetoprotein concentration based on liquid-phase binding assay using anion exchange chromatography and sulfated peptide introduced antibody. J Immunol Methods 212:161–168PubMedCrossRef Yamagata Y, Katoh H, Nakamura K, Tanaka T, Satomura S, Matsuura S (1998) Determination of alpha-fetoprotein concentration based on liquid-phase binding assay using anion exchange chromatography and sulfated peptide introduced antibody. J Immunol Methods 212:161–168PubMedCrossRef
44.
go back to reference Yamagata Y, Shimizu K, Nakamura K, et al. (2003) Simultaneous determination of percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein and alpha-fetoprotein concentration using the LiBASys clinical auto-analyzer. Clin Chim Acta 327:59–67PubMedCrossRef Yamagata Y, Shimizu K, Nakamura K, et al. (2003) Simultaneous determination of percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein and alpha-fetoprotein concentration using the LiBASys clinical auto-analyzer. Clin Chim Acta 327:59–67PubMedCrossRef
45.
go back to reference El-Serag HB, Mason AC, Key C (2001) Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 33:62–65PubMedCrossRef El-Serag HB, Mason AC, Key C (2001) Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 33:62–65PubMedCrossRef
46.
go back to reference Hamamura K, Shiratori Y, Shiina S, et al. (2000) Unique clinical characteristics of patients with hepatocellular carcinoma who present with plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein. Cancer 88:1557–1564PubMedCrossRef Hamamura K, Shiratori Y, Shiina S, et al. (2000) Unique clinical characteristics of patients with hepatocellular carcinoma who present with plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein. Cancer 88:1557–1564PubMedCrossRef
47.
go back to reference Koike Y, Shiratori Y, Sato S, et al. (2001) Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 91:561–569PubMedCrossRef Koike Y, Shiratori Y, Sato S, et al. (2001) Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 91:561–569PubMedCrossRef
Metadata
Title
Clinical Evaluation of Lens Culinaris Agglutinin-Reactive α-Fetoprotein and Des-γ-Carboxy Prothrombin in Histologically Proven Hepatocellular Carcinoma in the United States
Authors
Brian I. Carr
Futoshi Kanke
Margaret Wise
Shinji Satomura
Publication date
01-03-2007
Published in
Digestive Diseases and Sciences / Issue 3/2007
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9541-2

Other articles of this Issue 3/2007

Digestive Diseases and Sciences 3/2007 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.